2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SPACSphere Acquisition Corp. and Mobilewalla announced on August 12, 2026 that they filed a Form S-4 registration statement with the SEC for their previously announced business combination. The registration statement has not yet become effective, and the transaction remains subject to shareholder and stockholder approval, SEC effectiveness, and other closing conditions. Shareholders should review the preliminary proxy statement/prospectus before any voting decision.
Form S-4 with a preliminary proxy statement/prospectus filed with the SEC on August 12, 2026
Combined company expected to operate as Covariate, Inc. and trade on Nasdaq or another U.S. national exchange
Transaction expected to close in the second half of 2026, subject to shareholder approvals and SEC effectiveness
Agenus approved a special, one-time performance-based stock option award to Chairman and CEO Garo H. Armen on August 10, 2026, covering 1,971,500 options with a 10-year term. The exercise price of $7.78 per share was set at Armen's request to match the price granted to other management on August 5, 2026, and it was above the August 10 closing price, so the options are not priced below the team's grants.
Award: 1,971,500 performance-based stock options with a 10-year term under the Amended and Restated 2019 Equity Incentive Plan
Exercise price: $7.78 per share, matching the August 5, 2026 management grants and above the August 10, 2026 closing price
Vesting: five equal tranches tied to the stock sustaining 3x, 4x, 5x, 6x and 8x the $7.78 measurement price for 30 consecutive days within a five-year period, with a minimum three-year service requirement
No acceleration on termination or change in control; the award is subject to the company's clawback policy
Cyngn reported second-quarter 2026 results with revenue of $144,459, up from $33,726 a year earlier, while its net loss widened to $6.4 million from $5.4 million as total costs rose 25%. The company said commercial execution was delayed relative to its expectations, and it has reduced management layers and changed sales leadership. Cash and short-term investments totaled $39.7 million at June 30, 2026, and the company reported no debt.
Q2 2026 revenue was $144,459, compared with $33,726 in Q2 2025.
Q2 2026 net loss was $(6.4) million, or $(0.45) per share, on about 14.1 million weighted-average shares, versus $(5.4) million, or $(2.70) per share, on about 2.0 million shares in Q2 2025.
Total costs and expenses rose $1.4 million, or 25%, to $6.9 million, mainly from a $1.2 million increase in research and development.
Cash and short-term investments were $39.7 million at June 30, 2026, versus $34.7 million at December 31, 2025.
BioStem Technologies reported second quarter 2026 results on August 12, 2026, with net revenue of $7.9 million, up 29% from $6.1 million in the first quarter but down from $11.0 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $26 million to $29 million, but posted a GAAP net loss of $9.0 million, or $0.52 per share, and cash and cash equivalents fell to $7.0 million at June 30, 2026.
Net revenue of $7.9 million, up 29% from $6.1 million in Q1 2026 and down from $11.0 million in Q2 2025
GAAP net loss of $9.0 million, or $0.52 per share, versus net income of $10,613 in Q2 2025; gross margin 61% versus 94% a year earlier
Full-year 2026 revenue guidance raised to $26 million to $29 million from $25 million to $29 million
Cash and cash equivalents of $7.0 million at June 30, 2026, compared with $13.7 million at the end of Q1 2026
Silence Therapeutics plc agreed on August 11, 2026 to sell 12,962,963 American Depositary Shares at $13.50 each in an underwritten public offering, with expected gross proceeds of about $175 million, up from the approximately $150 million announced on August 10. The company expects net proceeds of about $164.0 million, or about $188.7 million if underwriters fully exercise their option, and the offering is expected to close on August 13, 2026, which would add new shares for existing shareholders.
Offering of 12,962,963 ADSs at $13.50 per ADS, with underwriters buying at $12.69 per ADS
Expected net proceeds of about $164.0 million, or about $188.7 million with full exercise of the 30-day option for 1,944,444 additional ADSs
Joint book-running managers are Jefferies LLC and Morgan Stanley & Co. LLC; closing expected on or about August 13, 2026
Scilex Holding Company agreed on August 8, 2026 to set up an uncommitted revolving credit line of up to $20,000,000 in favor of Vivasor, Inc., a related party whose CEO is Scilex CEO Dr. Henry Ji. The company has no obligation to fund any drawdown, and each advance is at its sole discretion, so the line creates a possible future cash or stock outflow rather than an immediate one.
Maximum aggregate principal of up to $20,000,000 with a 120-month maturity from August 8, 2026
Interest at 5% per annum, accruing from each funded drawdown; Vivasor may prepay without penalty
Company may fund drawdowns in cash, freely tradable Scilex securities, or Datavault AI, Inc. common stock it holds, or a combination
Dr. Henry Ji is Scilex's CEO, President and Chairperson and also CEO of Vivasor; the Board and Audit Committee approved the note
GMR Solutions reported second-quarter 2026 net revenue of $1,490.3 million, up 3.3%, but swung to a net loss of $28.3 million from net income of $80.8 million a year earlier. Adjusted EBITDA fell 11.8% to $284.5 million, and the company reaffirmed its full-year 2026 guidance, which means shareholders should weigh the revenue growth against lower profit.
Q2 2026 net revenue was $1,490.3 million, up 3.3% from $1,442.0 million in Q2 2025.
Q2 2026 net loss was $28.3 million, compared with net income of $80.8 million in Q2 2025; adjusted EBITDA was $284.5 million, down 11.8%.
Full-year 2026 guidance was reaffirmed: net revenue of $5,890 million to $6,180 million and adjusted EBITDA of $1,135 million to $1,195 million.
The CFO said the prior-year period benefited from a $74.3 million year-over-year difference in revenue estimate changes tied to No Surprises Act collections.
Santander Holdings USA reported second-quarter 2026 net income of $585 million, up 41.2% from the prior quarter and 17.5% from a year earlier, in a fixed income investor presentation furnished under Items 2.02 and 7.01. The filing also said the Federal Reserve approved the acquisition of Webster Financial Corporation on August 4, 2026, and that the deal is now expected to close on August 20, 2026.
Q2 2026 net income of $585 million, up 41.2% from Q1 2026 and up 17.5% from Q2 2025
Net interest income of $1.5 billion, up 1.7% from Q1 2026 and up 2.7% from Q2 2025
Federal Reserve approved the Webster Financial acquisition on August 4, 2026; closing expected August 20, 2026
CET1 ratio of 13.7% at June 30, 2026, up from 13.0% in Q1 2026
Pershing Square Inc. reported second quarter 2026 results on August 12, 2026, with the full press release and earnings presentation attached as Exhibit 99.1. The filing text provided does not include the quarter's revenue, profit or guidance figures, so the direction of results cannot be confirmed from it. The company also noted a $0.122 per share dividend paid July 21, 2026, and a shareholder call on August 13, 2026.
Q2 2026 results are in Exhibit 99.1; the revenue and profit figures are not in the text provided.
Dividend of $0.122 per common share paid July 21, 2026, to holders of record as of July 13, 2026.
Investor call on August 13, 2026 at 9:00 a.m. ET, followed by an X Spaces Q&A at 10:00 a.m. ET.
Investor withdrawals of $354 million (AUM) and $273 million (fee-paying AUM) from PSLP and PSINTL to take part in the PSUS IPO; no corporate income tax was incurred in Q2 2026, but the company expects to pay it in future periods.
Carpenter Technology appointed Kenneth J. Giacobbe, former Executive Vice President and Chief Financial Officer of Howmet Aerospace, to its Board of Directors effective August 11, 2026. Directors Howard Yu and Colleen Pritchett also said they will leave the board at the October 6, 2026 annual meeting, with Yu stepping down and Pritchett not standing for re-election; the filing says neither departure was due to a disagreement with the company.
Ken Giacobbe appointed to the Board effective August 11, 2026 as a Class III director, term ending at the 2028 annual meeting; he is independent and has no committee assignments yet
Howard Yu will step down as a director effective October 6, 2026; Colleen Pritchett will not run for re-election at the 2026 annual meeting
After October 6, 2026, the Board will have 10 members, 9 of them independent, down from 12 members with 11 independent
M-tron Industries (Mtron) reported second-quarter 2026 results, with revenue up 13.8% to $15.1 million and net income up 19.9% to $1.9 million. Diluted earnings per share fell to $0.43 from $0.53, which the company attributes to more weighted shares outstanding after a rights offering completed in April 2026. Shareholders get higher sales and profit in dollar terms, but per-share earnings were diluted, and management will discuss the results on a call on August 13, 2026.
Revenue of $15.1 million for the quarter, up 13.8% from $13.3 million a year earlier
Net income of $1.9 million, up 19.9%; diluted EPS of $0.43 versus $0.53, down 18.9%
Diluted EPS decline attributed to higher weighted shares outstanding from the rights offering completed in April 2026
Backlog of $84.0 million as of June 30, 2026, up 37.2% from $61.2 million a year earlier; conference call August 13, 2026 at 10:30 a.m. ET
On August 12, 2026, The Charles Schwab Corporation issued $2.6 billion of fixed-to-floating rate senior notes in two tranches, under a registration statement on Form S-3. The filing reports net proceeds of approximately $2,582 million after underwriting discounts, commissions and estimated offering expenses. The filing discloses new debt financing and does not describe any change to operations or results.
$1.25 billion of 5.108% Fixed-to-Floating Rate Senior Notes due 2032
$1.35 billion of 5.655% Fixed-to-Floating Rate Senior Notes due 2037
Net proceeds of approximately $2,582 million after underwriting discounts and offering expenses
Underwriting agreement dated August 10, 2026 with BofA Securities, Citigroup, Morgan Stanley, TD Securities and Wells Fargo Securities; trustee is The Bank of New York Mellon Trust Company, N.A.
Dolphin Entertainment reported second-quarter 2026 revenue of $14.4 million, up 2.5% from a year earlier, and first-half revenue of $27.2 million, up 3.8%. Net loss rose to $1.6 million from $1.4 million, and adjusted EBITDA fell to about $243,000 from about $628,000, as retention bonuses and litigation-related legal costs weighed on results.
Q2 2026 revenue was $14.4 million versus $14.1 million in Q2 2025; H1 2026 revenue was $27.2 million versus $26.3 million.
Q2 2026 operating loss was $1.0 million versus $0.1 million in Q2 2025; net loss was $1.6 million, or $(0.13) per share, unchanged from the prior-year loss per share.
Retention bonuses of $360,000 and litigation-related costs of about $0.4 million affected the quarter; the company says the bonuses are not expected to recur.
Cash and cash equivalents were $7.7 million at June 30, 2026, down from $8.8 million at December 31, 2025.
Tecogen reported second-quarter 2026 revenue of $5.75 million, down 21.2% from $7.29 million a year earlier, and a net loss of $2.15 million, or $(0.07) per share, versus a net loss of $1.46 million, or $(0.06) per share, in the same period of 2025. Management attributed the wider loss to lower Products segment gross profit and higher operating expenses, and said it expects third-quarter product revenue to exceed the first two quarters of 2026.
Q2 2026 Products revenue fell 64.0% to $1.13 million, while Services revenue rose 10.3% to $4.38 million.
Six-month net loss was $4.27 million, compared with $2.12 million a year earlier; cash and cash equivalents were $6.78 million at June 30, 2026.
Non-data center backlog was approximately $8 million, with $2 million or more in additional orders expected over the next few months, according to the CEO.
The company will hold an earnings conference call on August 13, 2026, at 9:30 am ET, with slides furnished as Exhibit 99.2.
CuriosityStream reported second-quarter 2026 revenue of $23.2 million, up from $19.0 million a year earlier, with net income of $8.9 million compared with $0.8 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and declared a $0.085 quarterly dividend, which matters to shareholders because it reflects higher reported profit and a higher outlook.
Q2 2026 revenue was $23.2 million, up 22% from $19.0 million in Q2 2025; licensing revenue was $14.1 million, up 48%.
Q2 2026 net income was $8.9 million, or $0.15 per diluted share, versus $0.8 million in Q2 2025; adjusted EBITDA was $11.4 million versus $3.0 million.
Full-year 2026 revenue guidance is $77 million to $82 million, and full-year adjusted EBITDA guidance is $18 million to $22 million.
Quarterly dividend of $0.085 per share is payable September 18, 2026, to holders of record on September 4, 2026.
On August 7, 2026, Radiant Logistics entered into an amended and restated $200 million secured revolving credit facility with Bank of America as administrative agent, replacing a credit agreement dated August 5, 2022. The company says the new facility lowers borrowing costs, removes the credit spread adjustment, extends maturity to 2031 and enlarges the accordion to $100 million. For shareholders, the filing shows more borrowing capacity and new terms, with the company stating it had no net debt as of March 31, 2026.
Facility size is $200 million, with a five-year term maturing August 7, 2031
Pricing is SOFR plus 137.5 to 212.5 basis points, a reduction from the prior facility
Accordion feature increased from $75 million to $100 million for future acquisitions
Covenants require a maximum net leverage ratio of 3.0x and a minimum interest coverage ratio of 3.0x; as of March 31, 2026, $25.0 million was drawn and $39.6 million in cash was on hand
Reddit's Chief Legal Officer and Corporate Secretary, Benjamin Lee, notified the company on August 12, 2026 that he will step down effective September 14, 2026. Reddit expects to appoint Paul Cappuccio to succeed him in both roles, and Lee will stay on as an employee through September 25, 2026 to help with the transition.
Benjamin Lee steps down as Chief Legal Officer and Corporate Secretary effective September 14, 2026
Lee remains an employee through September 25, 2026 to assist with the transition
Reddit expects to appoint Paul Cappuccio as Chief Legal Officer and Corporate Secretary
Mexco Energy reported net income of $501,065 for the quarter ended June 30, 2026, up 107% from a year earlier, and operating revenues rose 13% to $1,983,169. Revenue growth came mainly from a 52% higher average oil price, partly offset by a 15% drop in oil production, which matters to shareholders because the company's earnings depend on both prices and output.
Net income was $501,065, or $0.24 per diluted share, versus $241,951, or $0.12 per diluted share, in the prior-year quarter.
Operating revenues were $1,983,169, up 13% from $1,756,940, driven by a 52% increase in average oil price.
Oil production fell 15% and natural gas production fell 9%, while the average natural gas price fell 49%.
The company spent approximately $2.1 million on oil and gas royalty property acquisitions, funded from existing cash, and expects drilling and completion costs of approximately $1.8 million for the fiscal year ending March 31, 2027.
Park Dental Partners reported second-quarter 2026 revenue up 5.1% to $66.2 million, but net income fell 47.5% to $1.3 million, or $0.22 per diluted share, from $2.6 million, or $1.45, a year earlier. The company also issued full-year 2026 outlook of $256.0 million to $260.0 million in revenue and $21.0 million to $23.0 million in Adjusted EBITDA, excluding the pending Village Family DSO acquisition.
Q2 2026 revenue rose 5.1% to $66.2 million; Adjusted EBITDA fell 1.7% to $7.4 million.
Q2 2026 diluted EPS was $0.22 versus $1.45 in Q2 2025; adjusted diluted EPS was $0.66 versus $1.88.
2026 outlook: revenue $256.0 million to $260.0 million; Adjusted EBITDA $21.0 million to $23.0 million, compared with 2025 actual revenue of $244.5 million and Adjusted EBITDA of $22.0 million.
Entered a definitive agreement to acquire Village Family DSO, expected to close later this year; the outlook does not include it.
EquipmentShare reported second-quarter 2026 revenue of $1,449 million, up 26% from a year earlier, with net income of $19 million compared with $16 million. Diluted earnings per share were $0.06 in both periods, and the company reiterated its 2026 outlook, which projects total revenue of $5,254 million to $5,682 million and Adjusted Core EBITDA of $1,946 million to $2,058 million.
Q2 2026 total revenue $1,449 million, up 26% from $1,147 million; Rental Segment revenue $908 million, up 39%
Net income $19 million vs. $16 million a year earlier; GAAP diluted EPS $0.06 in both periods
Adjusted Core EBITDA $531 million, up 34% from $395 million; includes $24 million of IPO Founders Awards stock compensation excluded from Adjusted Net Income
2026 outlook: total revenue $5,254 million to $5,682 million; Adjusted Core EBITDA $1,946 million to $2,058 million
TCGX Acquisition Corp., a blank check company, closed its initial public offering on August 6, 2026, selling 8,625,000 Class A ordinary shares at $10.00 per share, including the full exercise of the underwriters' over-allotment option, for gross proceeds of $86.25 million. The full $86.25 million from the offering and private placement was deposited in a trust account, and the company has 24 months to complete a business combination or redeem the public shares.
IPO of 8,625,000 Class A ordinary shares at $10.00 per share closed August 6, 2026, for gross proceeds of $86.25 million
Private placement of 522,500 Class A ordinary shares at $10.00 per share for $5.225 million; sponsor TCGX Sponsor, LLC bought 436,250 shares and Jefferies LLC bought 86,250 shares
$86.25 million ($10.00 per public share) placed in trust account with Odyssey Transfer and Trust Company as trustee; $862,500 underwriter's discount excluded
Company has until 24 months from the IPO closing to complete a business combination, and reported $3.5 million in cash as of August 6, 2026
Kimball Electronics reported fourth-quarter fiscal 2026 net sales of $371.6 million, down 2% from a year earlier but up 5% from the prior quarter. Adjusted diluted EPS was a loss of $0.01, compared with $0.34 a year earlier, while GAAP diluted EPS rose to $0.35 from $0.26, helped by a $15.0 million gain on disposal. The company guided fiscal 2027 net sales of $1,535 million to $1,560 million, which includes about $60 million from the Helvoet acquisition.
Q4 net sales $371.6 million vs. $380.5 million a year earlier; adjusted operating income $18.1 million vs. $19.6 million
Q4 GAAP diluted EPS $0.35 vs. $0.26; adjusted diluted EPS $(0.01) vs. $0.34
Fiscal 2026 net sales $1,431.4 million, down 4% from $1,486.7 million; adjusted diluted EPS $1.09 vs. $1.12
Fiscal 2027 guidance: net sales $1,535 million to $1,560 million (7% to 9% growth) and adjusted operating income of 4.4% to 4.7% of net sales
Janus Living, Inc. closed a registered underwritten public offering of 18,400,000 Class A-1 common shares on August 12, 2026, including 2,400,000 shares sold under the underwriters' option, which was exercised in full. The filing does not state the offering price or net proceeds, so the dollar size of the raise is not disclosed here.
Offering of 18,400,000 Class A-1 common shares closed August 12, 2026, including 2,400,000 option shares
Underwriting Agreement dated August 10, 2026, with BofA Securities, J.P. Morgan Securities and Wells Fargo Securities as representatives
Sold under Form S-11 registration statement (File No. 333-298182); Healthpeak Investment Management, LLC is the external manager
Kontoor Brands said Joseph A. Alkire, currently executive vice president, chief financial officer and global head of operations, will become president and chief financial officer, while CEO Scott H. Baxter will remain chief executive officer and board chairman. The board's talent and compensation committee set Alkire's new pay effective August 12, 2026, which matters to shareholders as a leadership and pay change at the top of the company.
Joseph A. Alkire named President and Chief Financial Officer, effective August 12, 2026
Scott H. Baxter continues as Chief Executive Officer and Chairman of the Board
Alkire's pay: $900,000 base salary, bonus target of 120% of base salary, and $2,600,000 long-term incentive award opportunity
Crown Crafts reported first-quarter fiscal 2027 net sales of $16.8 million and net income of $2.1 million, compared with a net loss of $1.1 million a year earlier. Gross profit was helped by $3.7 million in tariff refunds, and the Board declared a $0.03 per share quarterly dividend. Stockholders also approved an amended 2021 Incentive Plan that raises the share reserve to 2,450,000 shares.
Net sales rose to $16.8 million from $15.5 million in the prior-year quarter ended June 29, 2025.
Net income was $2.1 million, or $0.19 per share, versus a net loss of $1.1 million, or $0.10 per share, a year earlier.
Gross profit included $3.7 million in tariff refunds; excluding refunds, gross margin was 25.6%, up 290 basis points year over year.
The $0.03 per share dividend is payable October 2, 2026 to holders of record on September 11, 2026.
Stem, Inc. reported results for the quarter ended June 30, 2026, with revenue down 12% year over year to $33.7 million and a net loss of $14.4 million, compared with net income of $202.5 million a year earlier that included a one-time gain on debt extinguishment. Adjusted EBITDA rose 63% to $6.2 million, and the company reaffirmed its full-year 2026 guidance across all metrics.
Revenue was $33.7 million, down from $38.4 million in Q2 2025, due to significantly reduced battery hardware resales and lower managed services revenue.
Software, services, and edge hardware revenue rose 1% to $33.4 million, with PowerTrack software revenue up 11% year over year.
Net loss was $14.4 million versus net income of $202.5 million in Q2 2025; the prior-year quarter included a one-time gain on extinguishment of debt.
Full-year 2026 guidance was reaffirmed, including revenue of $140 million to $190 million and adjusted EBITDA of $10 million to $15 million.
Solidion Technology reported second-quarter 2026 results in a press release furnished under Item 2.02. Net sales were $124,914, up from $4,000 a year earlier, mainly from government grant revenue, while the net loss widened to $2.9 million from a restated $2.1 million. The company said that after a $35 million private placement, substantial doubt about its ability to continue as a going concern has been alleviated.
Net sales of $124,914 for the quarter ended June 30, 2026, versus $4,000 a year earlier, mainly from government grant revenue.
Net loss of $2.9 million, or $0.35 per basic share, versus a restated $2,113,859 loss a year earlier; includes a $917,780 loss from change in fair value of derivative liabilities.
Cash and cash equivalents of $27.7 million at June 30, 2026, compared with $0.2 million at December 31, 2025.
A $35 million private placement closed June 9, 2026; the company said the going concern doubt was alleviated after it closed.
StubHub reported second-quarter 2026 revenue of $573.1 million, up 33% from a year earlier, and net income of $14.6 million compared with a net loss of $53.8 million in the prior-year quarter. The company raised its full-year 2026 gross merchandise sales (GMS) outlook to $10.1 billion to $10.3 billion and reiterated its adjusted EBITDA outlook of $400 million to $420 million, which signals improved operating results for shareholders.
Revenue of $573.1 million, up 33% from $430.3 million; GMS of $3.1 billion, up 34%
Net income of $14.6 million versus a net loss of $53.8 million a year earlier; adjusted EBITDA of $105.7 million, up 94%
Full-year 2026 GMS outlook raised to $10.1 billion to $10.3 billion; adjusted EBITDA outlook of $400 million to $420 million reiterated
Free cash flow of $309.7 million versus $9.7 million; year-to-date debt reduction of $200.0 million
FGI Industries reported second-quarter 2026 revenue of $31.9 million, up 2.9% from a year earlier, with gross margin rising to 33.4% from 28.1%. The company posted net income attributable to shareholders of $1.3 million, or $0.65 per diluted share, compared with a loss of $1.2 million, or $0.64 per diluted share, a year earlier. The company reaffirmed its fiscal 2026 guidance, which includes total net revenue of $134-141 million.
Q2 2026 revenue was $31.9 million, up 2.9% year over year; gross profit was $10.7 million, up 22.5%.
Operating income was $1.4 million, compared with an operating loss of $0.8 million in Q2 2025.
Diluted EPS was $0.65 versus a loss of $0.64 a year earlier; cash was $4.4 million and total liquidity was $7.9 million at June 30, 2026.
Fiscal 2026 guidance was reaffirmed, with total net revenue of $134-141 million and adjusted operating income of $0.7-2.5 million.
Fossil Group reported fiscal second-quarter 2026 net sales of $209.7 million, down 4.9% from $220.4 million a year earlier, and a net loss of $10.6 million, or $0.18 per diluted share, versus a $2.3 million loss, or $0.04 per share, in the prior-year quarter. The company also raised its full-year 2026 outlook, now calling for worldwide net sales to decline 3% to 5% and an adjusted operating margin of 4% to 6%, with positive free cash flow.
Gross margin rose 490 basis points to 62.4%, but operating expenses rose 7.9% to $127.6 million.
Operating income was $3.2 million, compared with $8.5 million in the second quarter of 2025; constant currency adjusted operating income was $8.6 million, compared with $4.3 million in the prior-year quarter.
Cash and cash equivalents were $79.0 million at July 4, 2026, and total debt was $203.0 million.
Full-year guidance: worldwide net sales down 3% to 5%, with a return to growth expected in the fourth quarter.
Centuri Holdings appointed Kelly Youngblood as Executive Vice President and Chief Financial Officer, replacing Gregory A. Izenstark, and Danielle Hunter as Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary, replacing Jason S. Wilcock, both effective August 12, 2026. The filing says the company expects to provide the departing officers with severance under their existing employment agreements, and it discloses Youngblood's pay package, which includes a $680,000 base salary.
Kelly Youngblood, CFO: base salary of $680,000, target annual bonus of 85% of base salary, and a restricted stock unit grant valued at $2,030,000
Youngblood severance if terminated without cause: lump sum of two times annual base salary, plus 24 months of subsidized COBRA premiums, outside a 24-month post-change-in-control window
Gregory A. Izenstark and Jason S. Wilcock are expected to sign severance agreements, each with a seven-day revocation period; the filing does not state the severance amounts
Centuri issued a press release on August 12, 2026 announcing the appointments (Exhibit 99.1)
Kailera Therapeutics reported a second-quarter 2026 net loss of $111.3 million, up from $28.9 million a year earlier, as research and development expenses rose to $101.1 million from $19.5 million. The company had $1,171.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund operations into mid-2028. For shareholders, the filing shows a much larger loss driven by expanded clinical development, and the statement of operations reports no revenue.
Q2 2026 net loss was $111.3 million, compared with $28.9 million in Q2 2025.
R&D expenses were $101.1 million versus $19.5 million; G&A expenses were $20.3 million versus $11.1 million.
Cash, cash equivalents and marketable securities totaled $1,171.8 million as of June 30, 2026, with runway into mid-2028.
Ribupatide oral has an active U.S. FDA IND; global Phase 3 obesity trial initiation is planned for the first half of 2027.
Ryman Hospitality Properties sold 5,100,000 new shares of common stock at $117.00 per share under an August 10, 2026 underwriting agreement with BofA Securities and J.P. Morgan. The underwriters exercised in full their option to buy 765,000 more shares, and the offering closed on August 12, 2026. The company received net proceeds of approximately $658 million, and the new shares add to the number of shares shareholders hold in the company.
Base offering: 5,100,000 shares at $117.00 per share, before underwriting discounts and commissions
Underwriters exercised their 30-day option in full on August 11, 2026, for an additional 765,000 shares
Offering closed on August 12, 2026, with net proceeds of approximately $658 million after discounts and estimated expenses
Sold under a prospectus supplement and base prospectus dated August 10, 2026, tied to a Form S-3 shelf registration
Marchex reported second-quarter 2026 revenue of $11.0 million, down from $11.7 million a year earlier, and a net loss of $0.4 million, or $(0.01) per diluted share, compared with net income of $0.1 million a year earlier. Adjusted EBITDA rose to $0.7 million from $0.6 million, but the Archenia acquisition, which closed July 1, 2026, is not included in these reported results, and the company gave a third-quarter pro forma combined revenue outlook of $16.0 million to $16.5 million.
Q2 2026 revenue was $11.0 million, compared with $11.7 million in Q2 2025.
Q2 2026 net loss was $0.4 million, or $(0.01) per diluted share, versus net income of $0.1 million, or $0.00 per share, a year earlier.
Adjusted EBITDA was $0.7 million, including $1.0 million of reorganization and acquisition-related costs; adjusted non-GAAP income per share was $0.00 versus $0.02.
Third-quarter 2026 pro forma combined outlook: revenue of $16.0 million to $16.5 million and adjusted EBITDA, net of reorganization and acquisition costs, of $2.3 million to $2.5 million.
Infleqtion reported second-quarter 2026 revenue of $12.6 million, up 116% year over year, and raised its full-year 2026 revenue outlook to approximately $43 million. The net loss widened to $25.5 million from $8.8 million a year earlier, and the company ended the quarter with $582 million in cash, cash equivalents, restricted cash and available-for-sale securities and no debt.
Q2 2026 revenue was $12.6 million, up 116% year over year; the company said growth was 100% organic and entirely from quantum
GAAP operating loss was $30.6 million, compared with $10.1 million in Q2 2025; non-GAAP operating loss was $17.0 million, compared with $7.3 million
2026 revenue outlook was raised to approximately $43 million, and the 30 logical qubit target was reiterated
Results included a $27.4 million temporary working-capital benefit from payroll taxes not yet remitted; the company expects to remit it in Q3
BitGo reported second-quarter 2026 revenue of $4.3 billion, up 79.6% from a year earlier, but swung to a net loss of $19.0 million from a net income of $38.3 million in Q2 2025. The same day, CFO Edward Reginelli said he will resign effective September 15, 2026, and the company has started a search for his successor.
Total revenue of $4.3 billion in Q2 2026, up 79.6% year-over-year and 14.7% sequentially, driven mainly by Digital Asset Sales
Net loss of $19.0 million, or $(0.16) per share, compared with net income of $38.3 million in Q2 2025, mainly due to an $18.8 million unrealized loss on digital assets
Adjusted EBITDA loss of $4.2 million; the company authorized a share repurchase program of up to $50 million
CFO Edward Reginelli to resign effective September 15, 2026, then serve in an advisory role during the transition
Resideo reported second quarter 2026 revenue of $1.98 billion, up 2% year over year, with net income of $97 million versus a net loss of $825 million a year earlier and diluted EPS of $0.51. The company also completed the spin-off of ADI Global Distribution on August 3, 2026, and named Shane Harrison Senior Vice President and Chief Financial Officer effective September 1, 2026.
Q2 2026 adjusted EPS was $0.83, up 26% from a year earlier, and adjusted EBITDA was $249 million, up 19%.
GAAP income from operations fell 26% to $131 million, with $31 million of business separation costs in the quarter.
Resideo initiated standalone outlook: third quarter 2026 revenue of $705 million to $730 million and full-year 2026 revenue of $2.90 billion to $2.95 billion.
AEVEX Corp. agreed on August 12, 2026 to acquire Maritime Applied Physics Corporation's parent-held BlackSea Technologies business in a deal with a $600 million enterprise value, plus up to $50 million in contingent consideration. The Company will pay mostly in cash and about 12.7 million newly issued Class A shares, which adds dilution for existing stockholders, and it expects BlackSea to generate $150 million in fiscal 2026 revenue.
Enterprise value of $600 million; up to $650 million including $50 million in performance-based contingent consideration tied to revenue and gross profit targets through December 31, 2027
Closing consideration includes about 12,727,273 Class A shares valued at $350 million ($27.50 per share) and cash, funded from cash on hand and existing credit facilities
Closing is expected in September 2026, subject to HSR antitrust clearance and NYSE listing approval; no stockholder vote is required
Company says BlackSea is expected to generate $150 million in FY 2026 revenue; issued shares are capped at 19.99% of outstanding stock and carry a 180-day transfer restriction
EnerSys reported first quarter fiscal 2027 net sales of $935.6 million, up 4.8% from a year earlier, and GAAP diluted EPS of $3.09 versus $1.46. Adjusted diluted EPS of $3.66 came in above the company's May 20 guidance range of $2.80 to $2.90. The Board also raised the quarterly dividend 10% to $0.2875 per share, and the company guided second quarter net sales to $955 million to $995 million.
Net sales of $935.6 million, up 4.8% from $893.0 million; GAAP diluted EPS of $3.09 versus $1.46.
Adjusted diluted EPS of $3.66, above the $2.80 to $2.90 guidance range; results include $30.9 million of tariff refunds.
Second quarter fiscal 2027 outlook: net sales of $955 million to $995 million and adjusted diluted EPS of $3.15 to $3.25.
Quarterly dividend raised 10% to $0.2875 per share, payable October 2, 2026, to holders of record as of September 18, 2026.
Blackstone Secured Lending Fund signed a fifth amendment to its senior secured credit agreement on August 10, 2026. The amendment extends the borrowing period and maturity of most revolving commitments, lowers total commitments from $2.425 billion to $2.375 billion, and resets the minimum shareholders' equity requirement.
Borrowing period for certain revolving commitments extended from August 4, 2029 to August 10, 2030.
Maturity for most revolving commitments extended from August 4, 2030 to August 10, 2031; $200.0 million of certain lenders' commitments still mature June 28, 2027.
Aggregate commitments changed from $2.425 billion to $2.375 billion, including revolving commitments of $1.9 billion and funded term loan commitments of $438.5 million.
The amendment also resets the minimum shareholders' equity and provides for payment of certain agreed fees.
Armata Pharmaceuticals reported second-quarter 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. Operating loss widened to $10.3 million from $6.8 million a year earlier, and the company's cash and equivalents were $24.0 million at June 30, 2026, so the profit does not reflect improved operations.
Q2 2026 grant and award revenue was $2.5 million, up from $2.2 million in Q2 2025.
Q2 2026 research and development expenses rose to $7.6 million and general and administrative expenses to $5.2 million, mainly from higher non-cash stock-based compensation.
Q2 2026 diluted loss per share was $0.27, compared with $0.45 in Q2 2025; basic earnings per share were $2.02.
Six-month net loss widened to $41.2 million from $22.8 million; cash and equivalents were $24.0 million at June 30, 2026.
ACRES Commercial Realty Corp. sold 2,220,000 shares of its 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock in a registered direct offering to institutional investors, under an agreement dated August 10, 2026. The offering settled on August 12, 2026, with gross proceeds of approximately $52.75 million before placement agent fees and offering expenses. Shareholders should note the new preferred shares rank in the company's capital structure alongside existing equity, and the filing does not state how the proceeds will be used.
2,220,000 Series C Preferred shares sold at $23.75 each
Approximately $52.75 million in gross proceeds before fees and expenses
Offering closed and shares settled on August 12, 2026
Seaport Global Securities LLC served as placement agent
Gaxos.ai reported record second-quarter 2026 revenue of $2.46 million, up 35.8% from the first quarter and up 1,337% from the second quarter of 2025, while advertising and marketing expense rose about 13.5%. GAAP net income was $241,056, or $0.02 per share, mainly from a gain on the sale of its gaming assets to Game Foundry AI, so the profit may not repeat in future quarters. The filing gives no financial guidance for future periods.
Q2 2026 revenue was $2.46 million, up 35.8% from $1.81 million in Q1 2026 and up 1,337% from $0.17 million in Q2 2025.
GAAP net income was $241,056, or $0.02 per basic and diluted share, primarily reflecting a gain from the gaming asset sale.
Advertising and marketing expense was $3,141,273 in Q2, compared with $2,766,824 in Q1 2026.
Cash and short-term investments were about $11.44 million at June 30, 2026, versus $11.71 million at March 31, 2026.
OLB Group entered an Equity Distribution Agreement with Maxim Group on August 7, 2026, allowing it to sell common stock through an at-the-market offering. The company filed a prospectus supplement registering up to $1.6 million of shares, and it has no obligation to sell any shares under the agreement. Shareholders could see dilution if the company sells shares under the program, and Maxim will receive a 3.0% commission on gross sales.
Agreement dated August 7, 2026, with Maxim Group LLC covers sales of common stock through an at-the-market offering.
Prospectus supplement registers up to $1.6 million of shares, issued under a shelf registration statement effective July 2, 2024.
Maxim receives a commission of 3.0% of gross sales price, and the company reimburses its expenses and legal fees.
The company may end the program on ten business days' written notice and has no obligation to sell any shares.
Atea Pharmaceuticals reported a narrower second-quarter net loss of $32.9 million, down from $37.2 million a year earlier, as lower research and development and general and administrative spending more than offset lower interest income. Cash and investments fell from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026. The release also restates the July C-BEYOND Phase 3 results and gives timing for C-FORWARD topline data and a planned new drug application, which shape the company's path to a possible US launch of BEM/RZR.
Net loss of $32.9 million, or $0.41 per share, for the three months ended June 30, 2026, versus $37.2 million, or $0.44 per share, a year earlier.
Research and development expenses fell to $28.2 million from $32.3 million; general and administrative expenses fell to $7.0 million from $9.1 million.
Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025.
C-FORWARD Phase 3 topline results are expected in early first quarter 2027; a new drug application submission is anticipated in the second quarter of 2027.
MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from a year earlier, while its net loss narrowed to $8.9 million from $12.4 million. The company reiterated full-year 2026 revenue guidance of $30 million to $32 million, so shareholders get a smaller loss alongside a shrinking top line.
Total revenue $7.3 million vs. $8.5 million in Q2 2025, down 15%; core revenue down 21% to $6.5 million
Net loss $8.9 million vs. $12.4 million a year earlier; operating expenses $15.8 million vs. $21.2 million
Full-year 2026 revenue guidance of $30 million to $32 million reiterated; year-end cash expected to be at least $130.5 million
Repurchased about $5.5 million of common stock to date under a $10 million buyback; cash and investments $141.9 million at June 30, 2026
Alto Neuroscience reported a second-quarter 2026 net loss of $27.6 million, up from $17.7 million a year earlier, as research and development spending rose to $22.1 million from $13.1 million. The company said it had about $338 million in pro forma cash after a July 2026 offering, which it expects to fund planned operations through 2030, and it added a Phase 3 monotherapy trial of ALTO-207 to its development plan.
Q2 2026 net loss was $27.6 million, versus $17.7 million in Q2 2025; net loss per share was $0.65 in both periods.
R&D expenses were $22.1 million versus $13.1 million; G&A expenses were $7.0 million versus $5.6 million.
Cash, cash equivalents, and restricted cash were $244.2 million at June 30, 2026, versus $177.0 million at December 31, 2025.
July 2026 registered direct offering raised gross proceeds of about $100.0 million; pro forma cash is about $338 million.
Lulus reported second quarter 2026 results for the period ended June 28, 2026, with net revenue down 17% year over year to $67.8 million. Net loss narrowed to $1.5 million from $3.0 million, and gross margin rose 330 basis points to 48.6%, but the company said revenue trends remain below historical levels. The company reaffirmed its fiscal 2026 outlook, including positive Adjusted EBITDA and capital expenditures of $2.0 million to $2.5 million.
Net revenue fell 17% to $67.8 million, driven by a 17% decrease in Total Orders Placed and higher return rates.
Net loss was $1.5 million, or $(0.52) per share, compared with a net loss of $3.0 million, or $(1.08) per share, a year earlier.
Gross margin increased to 48.6% from 45.3%, and inventory fell 23% to $28.6 million.
Lulus reaffirmed its fiscal 2026 outlook for positive Adjusted EBITDA and net revenue growth trend improvement.
Virgin Galactic reported a second-quarter 2026 net loss of $56 million, down from $67 million a year earlier, helped by an $8.6 million gain on extinguishment of debt. Revenue fell to $0.1 million from $0.4 million, and the company said its first commercial spaceflight has moved to February 2027 from the fourth quarter of 2026 to complete systems installations.
Net loss of $56 million versus $67 million in Q2 2025; revenue of $0.1 million versus $0.4 million
First commercial spaceflight moved to February 2027 from the fourth quarter of 2026
Free cash flow guidance: $(95) million to $(100) million in Q3 2026 and $(80) million to $(90) million in Q4 2026
Cash, cash equivalents and marketable securities of $286 million as of June 30, 2026
Connect Biopharma reported results for the three and six months ended June 30, 2026. Revenue rose to $2.8 million for the quarter, mainly from a regulatory milestone under its Simcere license, but the net loss widened to $17.3 million, or $0.27 per share, from $12.9 million, or $0.23 per share, a year earlier, as research and development expense nearly doubled. The company said its $31.5 million in cash, cash equivalents and short-term investments should fund operations for at least one year from the release date, and it expects topline data from its two Phase 2 Seabreeze STAT studies in September 2026.
Q2 2026 license and collaboration revenue was $2.8 million, versus $48,000 in Q2 2025, primarily from a regulatory-based milestone net of development cost sharing.
Q2 2026 research and development expense was $16.3 million, up from $8.8 million, mainly due to rademikibart development costs for the Seabreeze STAT studies.
Q2 2026 net loss was $17.3 million, or $0.27 per share, compared with $12.9 million, or $0.23 per share, in Q2 2025.
Cash, cash equivalents and short-term investments were $31.5 million as of June 30, 2026, down from $44.3 million at December 31, 2025; topline data from the Phase 2 studies are expected in September 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.